RNA-targeted degradation holds therapeutic potential but still needs more efficient tools. Here, authors develop dCasCMA, a platform that combines CRISPR targeting with a cellular degradation mechanism to efficiently degrade specific RNAs in live cells and in vivo, enabling multi-target therapies.
- Hui-Ping Wen
- Cong Yu
- Shu-Lin Liu
